



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

December 14, 2017

The National Stock Exchange of India Limited
Listing Department
Exchange Plaza, Bandra Kurla Complex
Bandra (East)
Mumbai 400 051

BSE Limited
Department of Corporate Services
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Sub: Qualified institutions placement of equity shares of face value Rs. 2 each (the "Equity Shares") by Natco Pharma Limited (the "Company") under the provisions of Chapter VIII of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended (the "SEBI ICDR Regulations"), and Section 42 of the Companies Act, 2013 (including the rules made thereunder) (the "QIP")

Dear Sir/Madam,

Please refer to our letter dated December 11, 2017 intimating you about the meeting of the Committee of Directors ("Committee") to be held on December 14, 2017 in respect of the QIP.

We wish to inform you that in respect of the QIP, the Committee at its meeting held today i.e. December 14, 2017, has *inter alia* passed the following resolutions:


- a. Approved the closure of the QIP today i.e. December 14, 2017;
- b. Determined and approved allocation of 10,000,000 Equity Shares at the issue price of Rs. 915 per Equity Share (including a premium of Rs. 913 per Equity Share) upon the closure of the Issue, which is at a discount of 2.41% (i.e. Rs. 22.63) per Equity Share, to the Floor Price of Rs. 937.63 per Equity Share, determined as per the formula prescribed under Regulation 85(1) of the SEBI ICDR Regulations, for the Equity Shares to be allotted to eligible qualified institutional buyers pursuant to the QIP amounting to an Issue size of Rs. 9,150 million; and
- c. Approved and adopted the placement document dated December 14, 2017, in connection with the QIP.
- d. Approved the issue of Confirmation of Allocation Note for allocation of Equity Shares to the Eligible QIBs.

We request you to take the above on record and the same be treated as compliance under the applicable regulations under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours Faithfully

For Natco Pharma Limited



M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)

